| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC0815 |
| Trial ID | ChiCTR1900025089 |
| Disease | B-Cell Acute Lymphoblastic Leukemia | Diffuse Large B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CTA101 |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | Phase I study for CTA101 Ucells injection in the treatment of relapsed or refractory CD19+ acute B-lymphocytic leukemia and diffuse large B-cell lymphoma |
| Year | 2019 |
| Country | China |
| Company sponsor | The First Affiliated Hospital of Xiamen University |
| Cohort1: B-ALL | |||||||||||
|
|||||||||||
| Cohort2: DLBCL | |||||||||||
|
|||||||||||